Baricitinib /INCB28050 /LY3009104/1187594-09-7
Inquiry
| Post Date: | Aug 18,2016 |
| Expiry Date: | Aug 18,2017 |
| Detailed Description: |
Cas No. :1187594-09-7
Quantity: 0.1Kilograms Specs:98%min Price:100 USD Kilograms Payment Method: T/T Baricitinib (INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. The related compound in JAK inhibitor is Tofacitinib, currently approved for the treatment of rheumatoid arthritis in the United States. |
| CAS Registry Number: | 1187594-09-7 |
| Synonyms: | ;2-(3-(4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;LY3009104;INCB028050; |
| Molecular Formula: | C16H17N7O2S |
| Molecular Weight: | 371.41668 |
| Molecular Structure: | 
|
| Company: | Shanghai Biopharmaleader Co.,Ltd [ China ] |
| Contact: | Brenda Xu |
| Tel: | 021-50180596 |
| Fax: | 021-57758967 |
| Email: | brenda@biopharmaleader.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
